MedTrace Logo

Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

NCT07151326 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-03

No results posted yet for this study

Summary

1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment.
2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Cabozantinib

All patients will be treated with cabozantinib at 60 mg once daily.

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Tri-Service General Hospital

    collaborator OTHER

  • Mackay Memorial Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Tsang-Wu Liu · Taiwan Cooperative Oncology Group, NHRI

  • Ying-Chun Shen · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07151326 on ClinicalTrials.gov